{"schema_version":"secwatch.filing_event.v1","accession":"0001847903-23-000158","form_type":"8-K","ticker":"CNTA","cik":"0001847903","company_name":"Centessa Pharmaceuticals plc","filed_at":"2023-08-24T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.735400+00:00","generated_at":"2026-06-11T04:22:38.221870+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.35,"calibrated_materiality_score":0.35,"confidence":"high","headline":"Centessa's oral OX2R agonist ORX750 preclinically reduces cataplexy and promotes wakefulness in narcolepsy mouse model","bullets":["ORX750 is a potent full agonist at human OX2R (EC50=0.11 nM) with >9,800-fold selectivity over OX1R.","In orexin/ataxin-3 narcolepsy mice, ORX750 increased wakefulness and consolidated wakefulness dose-dependently.","At 0.3 mg/kg, latency to sleep was 2.3 h (vs 0.69 h vehicle) and latency to cataplexy was 2.7 h (vs 1.3 h vehicle).","ORX750 also increased EEG gamma power during wakefulness and reduced cataplexy occurrences in active-phase EEG/EMG assays.","Company will present abstract at World Sleep Congress 2023 on October 25, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001847903-23-000158","json":"https://secwatch.observer/filing/0001847903-23-000158.json","markdown":"https://secwatch.observer/filing/0001847903-23-000158.md","text":"https://secwatch.observer/filing/0001847903-23-000158.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000158/0001847903-23-000158-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1847903/000184790323000158/cnta-20230822.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-11T04:22:38.221870+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}